dcsimg Aranesp® (darbepoetin alfa) – Transfusion Trends
› Email› Print

Annual transfusions have increased since 20101

In 2013, the annual percent of patients with at least
1 RBC transfusion had increased to 22%1

Transfusion Trends

The trend of increased transfusion rates was similar for all patient characteristics, including age, dialysis vintage, gender, and race1,*

Transfusion Trends

Based on the changing trend, CMS stated they will continue to monitor the rate of transfusions2


Aranesp® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.

Limitations of Use:

  • Aranesp® has not been shown to improve quality of life, fatigue, or patient well-being.
  • Aranesp® is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
CMS = Centers for Medicare & Medicaid Services; RBC = red blood cell.
References: 1. Data on file. Amgen; [Chronic Disease Research Group: Annual Transfusion Proportion and Rate in Patients Receiving Hemodialysis and Peritoneal Dialysis. August 2015]. 2. Centers for Medicare & Medicaid Services. Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Bad Debt Reductions for All Medicare Providers. [CMS- 1352-F]. Fed Regist. 2012;77:67450-67531. 42 CFR Parts 413 and 417.

Biotechnology by Amgen®